143 related articles for article (PubMed ID: 3542358)
1. Enzyme immunoassay for the quantitation of immunoglobulin M class antibodies to Salmonella minnesota R595 and Escherichia coli J5 lipopolysaccharides.
Vanesian MA; Fung G; Bagdasarian A
Diagn Microbiol Infect Dis; 1987 Jan; 6(1):11-25. PubMed ID: 3542358
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of Shwartzman-inducing activity by antibodies recognizing the Re core or lipid A structures of lipopolysaccharide from Salmonella minnesota R595 and Pseudomonas vesicularis JCM1477.
Mashimo J; Mizutani T; Mita A; Kasai N
Microbiol Immunol; 1991; 35(6):423-34. PubMed ID: 1921759
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides.
Aydintug MK; Inzana TJ; Letonja T; Davis WC; Corbeil LB
J Infect Dis; 1989 Nov; 160(5):846-57. PubMed ID: 2681436
[TBL] [Abstract][Full Text] [Related]
4. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.
Pollack M; Huang AI; Prescott RK; Young LS; Hunter KW; Cruess DF; Tsai CM
J Clin Invest; 1983 Dec; 72(6):1874-81. PubMed ID: 6358257
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria.
Siber GR; Kania SA; Warren HS
J Infect Dis; 1985 Nov; 152(5):954-64. PubMed ID: 2413146
[TBL] [Abstract][Full Text] [Related]
6. Immunochemical specificity of human antibodies to lipopolysaccharide from the J5 rough mutant of Escherichia coli O111:B4.
Schwartzer TA; Alcid DV; Numsuwan V; Gocke DJ
J Infect Dis; 1989 Jan; 159(1):35-42. PubMed ID: 2462603
[TBL] [Abstract][Full Text] [Related]
7. Age-related prevalence of human serum IgG and IgM antibody to the core glycolipid of Escherichia coli strain J5, as measured by ELISA.
Law BJ; Marks MI
J Infect Dis; 1985 Jun; 151(6):988-94. PubMed ID: 3889174
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.
Baumgartner JD; Heumann D; Calandra T; Glauser MP
J Infect Dis; 1991 Apr; 163(4):769-72. PubMed ID: 2010630
[TBL] [Abstract][Full Text] [Related]
9. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.
Bhattacharjee AK; Opal SM; Palardy JE; Drabick JJ; Collins H; Taylor R; Cotton A; Cross AS
J Infect Dis; 1994 Sep; 170(3):622-9. PubMed ID: 8077720
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5.
Baumgartner JD; O'Brien TX; Kirkland TN; Glauser MP; Ziegler EJ
J Infect Dis; 1987 Jul; 156(1):136-43. PubMed ID: 2439613
[TBL] [Abstract][Full Text] [Related]
11. An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region.
Appelmelk BJ; Verweij-Van Vught AM; MacLaren DM; Thijs LG
J Immunol Methods; 1985 Oct; 82(2):199-207. PubMed ID: 2413127
[TBL] [Abstract][Full Text] [Related]
12. Measurement in human sera of antibodies to lipopolysaccharide of Escherichia coli J5.
Appelmelk B; Gruteke P; Verweij-van Vught M; Maaskant J; Thijs B; MacLaren D
Microb Pathog; 1987 May; 2(5):391-3. PubMed ID: 3333804
[No Abstract] [Full Text] [Related]
13. Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality.
Greisman SE; Johnston CA
J Infect Dis; 1988 Jan; 157(1):54-64. PubMed ID: 2447200
[TBL] [Abstract][Full Text] [Related]
14. Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies.
Barclay GR; Scott BB
Infect Immun; 1987 Nov; 55(11):2706-14. PubMed ID: 3312008
[TBL] [Abstract][Full Text] [Related]
15. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteria.
Warren HS; Novitsky TJ; Bucklin A; Kania SA; Siber GR
Infect Immun; 1987 Jul; 55(7):1668-73. PubMed ID: 3298063
[TBL] [Abstract][Full Text] [Related]
16. Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.
de Jongh-Leuvenink J; Schellekens J; Verhoef J
Infect Immun; 1990 Feb; 58(2):421-6. PubMed ID: 2404871
[TBL] [Abstract][Full Text] [Related]
17. IgM, IgA and IgG class serum antibodies against Klebsiella pneumoniae and Escherichia coli lipopolysaccharides in patients with ankylosing spondylitis.
Mäki-Ikola O; Lehtinen K; Nissilä M; Granfors K
Br J Rheumatol; 1994 Nov; 33(11):1025-9. PubMed ID: 7981989
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of antibodies against gram-negative core antigens in rabbits, using an Escherichia coli J5 antigen-capture enzyme-linked immunosorbent assay.
Ruble RP; Cullor JS; Brooks DL
Am J Vet Res; 1999 Apr; 60(4):501-6. PubMed ID: 10211696
[TBL] [Abstract][Full Text] [Related]
19. Administration in vivo of recombinant interleukin 2 protects mice against septic death.
Weyand C; Goronzy J; Fathman CG; O'Hanley P
J Clin Invest; 1987 Jun; 79(6):1756-63. PubMed ID: 3294901
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria.
de Jongh-Leuvenink J; Bouter AS; Marcelis JH; Schellekens J; Verhoef J
Eur J Clin Microbiol; 1986 Apr; 5(2):148-51. PubMed ID: 2424754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
